Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician.

X
Trial Profile

A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Heat-labile enterotoxin E coli (Primary)
  • Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
  • Focus Pharmacodynamics
  • Sponsors Intercell USA; Valneva USA
  • Most Recent Events

    • 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
    • 09 Sep 2008 Planned end date changed from 1 Jun 2008 to 1 Aug 2008, according to ClinicalTrials.gov.
    • 08 Sep 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top